Andere Sprachen SAB Biotherapeutics, Inc.

Aktien

A3E4MT

US78397T2024

SABS

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 06.05.2024			% 5 Tage	% 1. Jan.
3,94 ^USD	-2,23 %		-5,97 %	-42,69 %

16.04.	SAB Biotherapeutics, Inc. gibt Update zur SAB-142-Studie	CI
02.04.	SAB BIOTHERAPEUTICS, INC. : HC Wainwright bekräftigt seine Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors	06.05.
SAB Biotherapeutics Provides SAB-142 Trial Update	16.04.
SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update	16.04.
SAB Biotherapeutics : Regulation FD Disclosure - Form 8-K	15.04.
SAB Biotherapeutics to Present at INNODIA Annual Meeting	08.04.
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference	04.04.
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results	01.04.
SAB Biotherapeutics : Reports Full Year 2023 Operating and Financial Results March 29, 2024 - Form 8-K	29.03.
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results	29.03.
SAB Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.03.
SAB Biotherapeutics, Navy Medical Research Command Initiate Safety Study for Influenza Treatment; Shares Decline	25.03.
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment	25.03.
Sab Biotherapeutics, Inc. Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment	25.03.
SAB Biotherapeutics to Present at the BIO CEO and Investor Conference	26.02.
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference	23.02.
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	09.02.
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	08.02.
SAB Biotherapeutics Executive Chairman Samuel Reich Adds CEO Role	02.02.
SAB Biotherapeutics Announces Executive Leadership Change	02.02.
SAB Biotherapeutics, Inc. Announces CEO Changes	02.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen SAB Biotherapeutics, Inc.

Aktien

A3E4MT

US78397T2024

SABS

Andere Sprachen

Filter